Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography

被引:25
作者
Loos, WJ
van Zomeren, DM
Gelderblom, H
Verweij, J
Nooter, K
Stoter, G
Sparreboom, A
机构
[1] Rotterdam Canc Inst, Daniel den Hoed Klin, Dept Med Oncol, NL-3008 AE Rotterdam, Netherlands
[2] Univ Rotterdam Hosp, NL-3008 AE Rotterdam, Netherlands
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2002年 / 766卷 / 01期
关键词
topotecan;
D O I
10.1016/S0378-4347(01)00432-7
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A reversed-phase HPLC method for the quantitative determination of total topotecan in human whole blood and unwashed erythrocytes has been developed and validated in terms of sensitivity, specificity, precision and accuracy. Linear calibration curves were constructed in the range of 0.20 to 50.0 ng/ml. The sample pre-treatment for whole blood involved a two-step extraction with methanol and perchloric acid. Prior to extraction, erythrocytes were separated from other blood components by centrifugation in MESED instruments. Separations were achieved on an Inertsil ODS-80A analytical column (150X4.6 nun, 5 mum particle size), eluted at 50 degreesC and a flow-rate of 1.00 ml/min, with a mixture of 100 mM ammonium acetate (pH 6.0)-tetrahydrofuran (94.6:5.4, v/v). Fluorescence detection was performed using excitation and emission wavelengths of 381 and 525 nm, respectively. With the applied method, 80% of topotecan was extracted out of whole blood. The lower limit of quantitation in whole blood was established at 0.20 ng/ml with within-run and between-run precisions, respectively, ranging from 1.7 to 9.3% and 1.5-6.1%, while the accuracy ranged from 100 to 113%. The described method will be used in clinical studies to explore the role of erythrocytes in the overall kinetic behavior of topotecan. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:99 / 105
页数:7
相关论文
共 14 条
[1]  
COLE DE, 1995, P 86 ANN M AM ASS CA, P363
[2]   Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography [J].
de Bruijn, P ;
de Jonge, MJA ;
Verweij, J ;
Loos, WJ ;
Nooter, K ;
Stoter, G ;
Sparreboom, A .
ANALYTICAL BIOCHEMISTRY, 1999, 269 (01) :174-178
[3]   Phase I pharmacologic study of oral topotecan and intravenous cisplatin: Sequence-dependent hematologic side effects [J].
de Jonge, MJA ;
Loos, WJ ;
Gelderblom, H ;
Planting, AST ;
van der Burg, MEL ;
Sparreboom, A ;
Brouwer, E ;
van Beurden, V ;
Mantel, MA ;
Doyle, E ;
Hearn, S ;
Ross, G ;
Verweij, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (10) :2104-2115
[4]   DESCRIPTION OF AN INSTRUMENT FOR SEPARATION OF RED-CELLS FROM PLASMA AND MEASUREMENT OF RED-CELL VOLUME [J].
DRIESSEN, O ;
HIGHLEY, MS ;
HARPER, PG ;
MAES, RAA ;
DEBRUIJN, EA .
CLINICAL BIOCHEMISTRY, 1994, 27 (03) :195-196
[5]   Population pharmacokinetic model for topotecan derived from phase I clinical trials [J].
Gallo, JM ;
Laub, PB ;
Rowinsky, EK ;
Grochow, LB ;
Baker, SD .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2459-2467
[6]   Erythrocytes and the transport of drugs and endogenous compounds [J].
Highley, MS ;
DeBruijn, EA .
PHARMACEUTICAL RESEARCH, 1996, 13 (02) :186-195
[7]  
Hinderling PH, 1997, PHARMACOL REV, V49, P279
[8]   Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans [J].
Loos, WJ ;
Verweij, J ;
Gelderblom, HJ ;
de Jonge, MJA ;
Brouwer, E ;
Dallaire, BK ;
Sparreboom, A .
ANTI-CANCER DRUGS, 1999, 10 (08) :705-710
[9]   Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine [J].
Loos, WJ ;
Stoter, G ;
Verweij, J ;
Schellens, JHM .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 678 (02) :309-315
[10]   Gender-dependent pharmacokinetics of topotecan in adult patients [J].
Loos, WJ ;
Gelderblom, HJ ;
Verweij, J ;
Brouwer, E ;
de Jonge, MJA ;
Sparreboom, A .
ANTI-CANCER DRUGS, 2000, 11 (09) :673-680